Last 23 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.13 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.86 | 5.96 | 6.10 | 6.05 | 2.98 | 1.89 | 1.71 | 2.38 | 3.82 | 2.49 | 2.20 | 2.91 | 2.66 | 3.04 | 2.74 | 1.24 | 1.38 | 1.07 | 1.53 | 1.93 | 0.52 |
| — | +216.0% | +257.7% | +153.5% | -22.1% | -24.4% | -22.4% | -18.1% | +43.8% | -17.9% | -19.8% | +134.2% | +92.7% | +183.8% | +79.3% | -35.4% | +164.9% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.8% | -12.3% | -12.2% | -12.5% | -10.3% | -9.0% | -8.4% | -7.2% | -6.5% | -4.9% | -6.1% | -10.7% | -9.2% | -5.4% | -4.7% | -4.9% | -4.6% | -5.3% | -5.0% | -3.2% | -4.6% |
| — | -36.9% | -43.9% | -73.0% | -57.6% | -83.9% | -37.9% | +32.3% | +29.1% | +10.3% | -30.6% | -118.2% | -100.6% | -2.8% | +6.2% | -51.1% | +1.1% | — | — | — | — | |
| ROA | -37.1% | -11.5% | -11.3% | -11.6% | -9.6% | -8.5% | -8.0% | -6.9% | -6.2% | -4.7% | -5.8% | -9.8% | -8.7% | -5.3% | -4.6% | -4.8% | -4.4% | -5.2% | -4.9% | -3.2% | -2.9% |
| — | -35.6% | -42.1% | -68.5% | -54.2% | -80.1% | -38.0% | +30.1% | +28.3% | +10.7% | -26.6% | -106.8% | -95.0% | -2.0% | +6.9% | -49.1% | -52.5% | -31.6% | +8.2% | +86.1% | — | |
| ROIC | -44.8% | -12.4% | -12.7% | -13.3% | -11.4% | -10.8% | -9.8% | -8.5% | -7.8% | -8.3% | -11.4% | -23.2% | -144.6% | -109.6% | -113.7% | -137.2% | -150.5% | -296.5% | -1047.1% | — | — |
| — | -15.1% | -29.3% | -55.6% | -45.3% | -29.5% | +13.5% | +63.2% | +94.6% | +92.4% | +90.0% | +83.0% | +3.9% | +63.0% | +89.1% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| — | -20.8% | -22.3% | +23.6% | +21.0% | +17.1% | +13.7% | -43.0% | -36.6% | -33.1% | +60.0% | +212.7% | +178.9% | +165.6% | +12.1% | +159.4% | +160.7% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.67 | 14.91 | 20.49 | 14.67 | 17.71 | 21.94 | 22.78 | 23.81 | 29.55 | 36.46 | 44.83 | 13.80 | 22.14 | 44.54 | 67.00 | 45.13 | 48.73 | 50.83 | 59.99 | 84.09 | 65.75 |
| — | -32.1% | -10.1% | -38.4% | -40.1% | -39.8% | -49.2% | +72.5% | +33.5% | -18.1% | -33.1% | -69.4% | -54.6% | -12.4% | +11.7% | -46.3% | -25.9% | +40.7% | -34.6% | +922.4% | — | |
| Quick Ratio | 14.67 | 14.91 | 20.49 | 14.67 | 17.71 | 21.94 | 22.78 | 23.81 | 29.55 | 36.46 | 44.83 | 13.80 | 22.14 | 44.54 | 67.00 | 45.13 | 48.73 | 50.83 | 59.99 | 84.09 | 65.75 |
| — | -32.1% | -10.1% | -38.4% | -40.1% | -39.8% | -49.2% | +72.5% | +33.5% | -18.1% | -33.1% | -69.4% | -54.6% | -12.4% | +11.7% | -46.3% | -25.9% | +40.7% | -34.6% | +922.4% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | -4792.60 | -762.57 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TYRA stock.
Tyra Biosciences, Inc.'s current P/E is -9.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tyra Biosciences, Inc.'s business trajectory between earnings reports.